Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

493.91
-0.7200-0.15%
Volume:133.64K
Turnover:66.21M
Market Cap:21.18B
PE:17.67
High:497.70
Open:497.70
Low:491.26
Close:494.63
52wk High:609.35
52wk Low:408.75
Shares:42.89M
Float Shares:39.35M
Volume Ratio:0.19
T/O Rate:0.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.95
EPS(LYR):27.86
ROE:19.31%
ROA:11.61%
PB:3.31
PE(LYR):17.73

Loading ...

United Therapeutics EVP, General Counsel Paul A. Mahon Disposes of USD 4.12 Million in Common Shares

Reuters
·
Sep 19

United Therapeutics CEO Martine A. Rothblatt Disposes of 9,500 Shares Worth USD 4.76 Million

Reuters
·
Sep 17

Bellevue Flags US Healthcare Innovation as Driving Fresh Investment Opportunities

Reuters
·
Sep 14

United Therapeutics CEO Martine A. Rothblatt Disposes of USD 3.94 Million in Common Shares

Reuters
·
Sep 11

United Therapeutics Announces New Accelerated Share Repurchase

TIPRANKS
·
Sep 09

United Therapeutics CEO Martine Rothblatt Disposes of Common Shares Worth $4.64 Million

Reuters
·
Sep 09

United Therapeutics to Repurchase $478 Million of Shares

MT Newswires Live
·
Sep 08

United Therapeutics Corporation - Final Settlement of Asr Expected in Q4 2026

THOMSON REUTERS
·
Sep 08

United Therapeutics Corporation - to Pay $477.60 Mln to Citi on or Around Sept 10, 2026

THOMSON REUTERS
·
Sep 08

United Therapeutics Corporation - to Receive Initial Delivery of 75% of Repurchased Shares Based on Sept 8, 2026 Price

THOMSON REUTERS
·
Sep 08

United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization

THOMSON REUTERS
·
Sep 08

United Therapeutics CEO Martine Rothblatt Reports Disposal of 9,406 Common Shares Worth $4.64 Million

Reuters
·
Sep 04

Wells Fargo Reaffirms Their Buy Rating on United Therapeutics (UTHR)

TIPRANKS
·
Sep 02

Analysts Have Conflicting Sentiments on These Healthcare Companies: United Therapeutics (UTHR) and Medtronic (MDT)

TIPRANKS
·
Sep 02

United Therapeutics Says FDA Accepts Tyvaso sNDA for Idiopathic Pulmonary Fibrosis Review

Reuters
·
Sep 02

United Therapeutics Corporation - FDA Review Expected to be Complete in Late April 2027

THOMSON REUTERS
·
Sep 02

United Therapeutics Corporation Announces FDA Acceptance of Supplemental New Drug Application for Nebulized Tyvaso® to Treat Idiopathic Pulmonary Fibrosis

THOMSON REUTERS
·
Sep 02

United Therapeutics Chairperson, CEO Rothblatt Disposes of Common Shares Worth $4.85 Million

Reuters
·
Sep 02

United Therapeutics Executives to Speak at Wells Fargo Healthcare Investor Conference

Reuters
·
Sep 01

United Therapeutics (UTHR) Will Present Phase 3 Data At European Congresses

Simply Wall St.
·
Aug 30